<DOC>
	<DOCNO>NCT01523587</DOCNO>
	<brief_summary>This randomise , open-label phase III trial perform patient advance squamous cell carcinoma lung require second-line treatment receive first-line platinum-based chemotherapy . The primary objective trial compare efficacy BIBW 2992 erlotinib second-line treatment group patient .</brief_summary>
	<brief_title>LUX-Lung 8 : A Phase III Trial Afatinib ( BIBW 2992 ) Versus Erlotinib Treatment Squamous Cell Lung Cancer After Least One Prior Platinum Based Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Inclusion criterion : 1 . Diagnosis advance stage NSCLC squamous histology . 2 . Platinumbased doublet chemotherapy 1st line treatment Stage IIIB/IV NSCLC . 3 . Eligible receive 2nd line therapy opinion investigator . 4 . Measurable disease accord RECIST 1.1 . 5 . Adequate Performance Status . 6 . Availability tumour tissue material correlative study . Archived tumour tissue acceptable . 7 . Adequate organ function . 8 . Age = 18 year . 9 . Written inform consent consistent ICHGCP guideline . Exclusion criterion : 1 . Prior treatment EGFR direct small molecule antibody . 2 . Radiotherapy within 4 week prior randomization . 3 . Active brain metastasis . 4 . Any current malignancy malignancy diagnose within past three ( 3 ) year ( basalcell carcinoma skin , situ cervical cancer , situ prostate cancer ) . 5 . Known preexist interstitial lung disease . 6 . Significant recent acute gastrointestinal disorder diarrhoea major symptom 7 . Any concomitant serious illness organ system dysfunction opinion investigator would either compromise patient safety interfere evaluation safety test drug . 8 . Women childbearing potential men able father child , unwilling abstinent use adequate contraception prior study entry , duration study participation least 2 month treatment end . 9 . Female patient childbearing potential ( see Section 4.2.3.3 ) : 1. nurse 2. pregnant 3. use acceptable method birth control , plan continue use method throughout study and/or agree submit pregnancy test require protocol . 10 . Active hepatitis B infection ( define presence Hep B DNA ) , active hepatitis C infection ( define presence Hep C RNA ) and/or know HIV carrier . 11 . Known suspected active drug alcohol abuse opinion investigator . 12 . Any contraindication therapy afatinib erlotinib . 13 . Known hypersensitivity erlotinib , afatinib excipients trial drug . 14 . Major surgery within 4 week start study treatment . 15 . Prior participation afatinib clinical study , even assign afatinib . 16 . Use investigational drug within 4 week randomisation ( unless long time period require local regulation guideline investigational product ) . 17 . Patients without Progression lung cancer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>